This product acts specifically on the gastric mucosal parietal cells, reducing the activity of H/KATPase in the parietal cells, thereby inhibiting the secretion of gastric acid. Compared with omeprazole and lansoprazole, this product has a weaker inhibitory effect on cytochrome P450-dependent enzymes. No adverse effects were found in either short-term or long-term administration of pantoprazole. This drug is non-carcinogenic, does not impair fertility, and does not induce teratogenesis. After 2.5 years of continuous medication, there were no changes in various experimental parameters of liver enzymology and cholesterol metabolism.

Proteolytic enzyme. It can dissolve blood clots, inhibit thrombosis, and improve microcirculation.

Proteolytic enzyme. It can dissolve blood clots, inhibit thrombosis, and improve microcirculation.

This product is a chemical semi-synthetic clindamycin derivative with no antibacterial activity in vitro. It is hydrolyzed into clindamycin after entering the body and shows pharmacological activity. The antibacterial spectrum, antibacterial activity and therapeutic effect are the same as those of clindamycin, and its fat solubility and permeability are better than those of clindamycin. It can be administered by intramuscular injection and intravenous drip. The antibacterial effect is 4 to 8 times stronger than that of lincomycin, with good absorption and high bone concentration, and good efficacy against anaerobic infections. It has strong antibacterial activity mainly against Gram-positive cocci (such as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus, Streptococcus pneumoniae, Micrococcus, etc.) and anaerobic bacteria (such as Clostridium, Bacteroides, Clostridium, Propionibacterium, Eubacterium, anaerobic cocci, etc.).

This product is a chemical semi-synthetic clindamycin derivative with no antibacterial activity in vitro. It is hydrolyzed into clindamycin after entering the body, showing the same antibacterial spectrum, antibacterial activity and therapeutic effect as clindamycin. Its fat solubility and permeability are better than those of clindamycin, and it can be administered by intramuscular injection and intravenous drip. Its antibacterial effect is 4 to 8 times stronger than that of lincomycin, with good absorption and high bone concentration, and significant efficacy against anaerobic infections. It mainly has strong antibacterial activity against Gram-positive cocci (such as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus, Streptococcus pneumoniae, Micrococcus, etc.) and anaerobic bacteria (such as Clostridium, Bacteroides, Clostridium, Propionibacterium, Eubacterium, anaerobic cocci, etc.).